<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3231">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01982201</url>
  </required_header>
  <id_info>
    <org_study_id>RDEA594-130</org_study_id>
    <nct_id>NCT01982201</nct_id>
  </id_info>
  <brief_title>Antacid Interaction Study</brief_title>
  <official_title>A Phase 1, Randomized, Open-Label, Drug-Drug Interaction Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interaction Between Lesinurad and Calcium Carbonate and Aluminum/Magnesium Hydroxide-Containing Antacids in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ardea Biosciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ardea Biosciences, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the potential effects of calcium carbonate and aluminum/magnesium
      hydroxide-containing antacids on the pharmacokinetics (PK) and pharmacodynamics (PD) of
      lesinurad in healthy, adult male subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, lesinurad and antacid will be administered in the fed state, antacid doses
      will be attenuated to reflect the more commonly used doses, baseline PD assessments will be
      performed both in presence and absence of antacid treatment, and the sequence of treatments
      (lesinurad +/- antacid) will be randomized.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>PK profile of lesinurad from plasma and urine</measure>
    <time_frame>Day 2 and Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Plasma in terms of maximum observed concentration (Cmax), time of occurrence of maximum observed concentration (Tmax), area under the concentration-time curve (AUC), apparent terminal half-life (t½), renal clearance (CLR), and adverse event (Ae).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PD profile of Lesinurad  from serum and urine</measure>
    <time_frame>Day 2 and Day 7</time_frame>
    <safety_issue>No</safety_issue>
    <description>Serum PD in terms of serum urate concentration, urine uric acid excretion amount, renal clearance of uric acid, and fractional excretion of uric acid.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events and Changes in Laboratory, Electrocardiogram, and Vital Signs Parameters</measure>
    <time_frame>5 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lesinurad and Tums</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: 240 mL water or  240 mL water and Tums Day 2: Lesinurad 400 mg or  Lesinurad 400 mg and Tums; Day 6: 240 mL water and Tums or 240 mL water; Day 7: Lesinurad 400 mg and Tums or Lesinurad 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lesinurad and MINTOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: 240 mL water or 240 mL water and MINTOX ; Day 2: Lesinurad 400 mg or Lesinurad 400 mg and MINTOX; Day 6: 240 mL water and MINTOX or 240 mL water; Day 7: Lesinurad 400 mg and MINTOX or Lesinurad 400 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lesinurad 400 mg</intervention_name>
    <arm_group_label>Lesinurad and Tums</arm_group_label>
    <arm_group_label>Lesinurad and MINTOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tums 500 mg and 750 mg</intervention_name>
    <arm_group_label>Lesinurad and Tums</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MINTOX 10 mL</intervention_name>
    <arm_group_label>Lesinurad and MINTOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a body weight ≥ 50 kg (110 lbs) and body mass index ≥ 18 and ≤ 30 kg/m2.

          -  Subject is free of any clinically significant disease or medical condition, per the
             Investigator's judgment

        Exclusion Criteria:

          -  Subject has a history or suspicion of kidney stones.

          -  Subject has undergone major surgery within 3 months prior to Screening.

          -  Subject donated blood or experienced significant blood loss (&gt;450 mL) within 12 weeks
             prior to Screening or gave a plasma donation within 4 weeks prior to Screening.

          -  Subject has inadequate venous access or unsuitable veins for repeated venipuncture.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. Hall</last_name>
    <role>Study Director</role>
    <affiliation>Ardea Biosciences, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 16, 2014</lastchanged_date>
  <firstreceived_date>November 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antacids</mesh_term>
    <mesh_term>Aluminum hydroxide, magnesium hydroxide, drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
